Matt Jacobsen

ESTP Congress
matt.jacobsen@astrazeneca.com
,

Following a veterinary degree at Cambridge, Matt undertook an anatomic pathology residency at Cornell University, obtaining board certification with the American College of Veterinary Pathologists in 2000. Matt returned to the UK and was a senior and then Chief pathologist at Syngenta’s Central Toxicology Laboratory where he supported a wide range of regulatory toxicology and investigative toxicology studies for Syngenta agrochemicals, with the lab also acting as a CRO for agrochemicals and pharma. He took a particular interest in neurotoxicity and developmental neurotoxicity studies. Matt then joined the Safety Assessment Department of AstraZeneca at Alderley Park in the UK as a senior pathologist, supporting oncology, infection and respiratory and Inflammation therapy areas. He was then appointed Director of the clinical pathology and biomarker group in the UK which provided support for routine preclinical toxicology studies, as well as Phase I clinical trials in man. Having managed the biomarker group at AstraZeneca for a number of years, Matt remained at AZ, where he was interim Global Head of Pathology, Head of European Pathology, and is currently a Senior Director in the Pathology department, and therapy area Pathology lead for vaccines and immune therapy. He also has accountability for drafting responses to regulatory authorities, and has remained an active project pathologist involved in the assessment of early safety and efficacy studies, as well as peer review of outsourced toxicology studies to include rodent carcinogenicity.